Literature DB >> 30205963

Diagnostic performance of GM-CSF and IL-2 in response to long-term specific-antigen cell stimulation in patients with active and latent tuberculosis infection.

María Elvira Balcells1, Cinthya Ruiz-Tagle2, Camila Tiznado3, Patricia García4, Rodrigo Naves5.   

Abstract

BACKGROUND: A simple blood test for detecting active tuberculosis (TB) could be key to this epidemic containment, given that a large proportion of patients are unable to produce sputum for testing. Currently available interferon-γ release assays (IGRAs) are inadequate to diagnose active TB, with reported pooled sensitivity and specificity both under 81%.
OBJECTIVE: To explore whether cytokines/chemokines other than interferon-γ in response to long-term cell stimulation could improve the ability to distinguish between different TB infection status.
METHODS: We prospectively enrolled subjects with newly diagnosed pulmonary TB and their household contacts in Santiago. All contacts were tested with IGRA. Peripheral blood mononuclear cells were obtained and antigen-specific stimulated for 72 h before collecting their culture supernatants.
RESULTS: Subjects with active TB displayed markedly low cytokines/chemokines secretion upon PBMC stimulation, with lower GM-CSF being the best differentiator from IGRA(+) contacts, with 71% (95% CI 53-85) sensitivity, 86% (95% CI 65-97) specificity and AUC = 0.79 (p = 0.0003). On the other hand, when compared to the uninfected IGRA(-) contacts, higher level of IL-2 secretion was the best indicator of active TB, with 73.5% (95% CI 56-87) sensitivity, 85% (95% CI 66-96) specificity and AUC = 0.79 (p = 0.0001). No single cytokine/chemokine released upon stimulation could accurately differentiate between active TB and all TB contacts grouped together.
CONCLUSION: GM-CSF and IL-2 provided the best yield to differentiate active TB from latent TB and from TB uninfected, respectively, with higher specificities than that reported for IGRAs. However, none of both resulted sensitive enough to be used as a stand-alone biomarker for active TB.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarkers; Cytokine; GM-CSF; IL-2; Immunodiagnostics; Mycobacterium tuberculosis; Tuberculosis

Mesh:

Substances:

Year:  2018        PMID: 30205963     DOI: 10.1016/j.tube.2018.08.006

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  5 in total

1.  Is interleukin-2 an optimal marker for diagnosing tuberculosis infection? A systematic review and meta-analysis.

Authors:  Xia Qiu; Huiqing Wang; Ying Tang; Xiaojuan Su; Long Ge; Yi Qu; Dezhi Mu
Journal:  Ann Med       Date:  2020-07-30       Impact factor: 4.709

Review 2.  Recent advances in the detection of interferon-gamma as a TB biomarker.

Authors:  Kaylin Cleo Januarie; Onyinyechi V Uhuo; Emmanuel Iwuoha; Usisipho Feleni
Journal:  Anal Bioanal Chem       Date:  2021-10-19       Impact factor: 4.142

3.  Cell-Mediated Immune Responses to in vivo-Expressed and Stage-Specific Mycobacterium tuberculosis Antigens in Latent and Active Tuberculosis Across Different Age Groups.

Authors:  Mariateresa Coppola; Raquel Villar-Hernández; Krista E van Meijgaarden; Irene Latorre; Beatriz Muriel Moreno; Esther Garcia-Garcia; Kees L M C Franken; Cristina Prat; Zoran Stojanovic; Maria Luiza De Souza Galvão; Joan-Pau Millet; Josefina Sabriá; Adrián Sánchez-Montalva; Antoni Noguera-Julian; Annemieke Geluk; Jose Domínguez; Tom H M Ottenhoff
Journal:  Front Immunol       Date:  2020-02-11       Impact factor: 7.561

4.  Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis.

Authors:  Xia Qiu; Tao Xiong; Xiaojuan Su; Yi Qu; Long Ge; Yan Yue; Yan Zeng; Wenxing Li; Peng Hu; Dezhi Mu
Journal:  BMC Infect Dis       Date:  2019-10-30       Impact factor: 3.090

Review 5.  Mesenchymal Stem Cells and Tuberculosis: Clinical Challenges and Opportunities.

Authors:  Xueying Zhang; Qi Xie; Ziyu Ye; Yanyun Li; Zhengping Che; Mingyuan Huang; Jincheng Zeng
Journal:  Front Immunol       Date:  2021-07-22       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.